With rates going higher, you have to wonder if AbbVie's worth the risk, even as it's among the safest, if not the safest stock in the group, because of these amazing franchises.

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the July 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options ...

Fintel reports that on May 14, 2025, Citigroup downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Neutral. Analyst ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation.

With rates going higher, you have to wonder if AbbVie’s worth the risk, even as it’s among the safest, if not the safest stock in the group, because of these amazing franchises. I think it ...

AbbVie (ABBV) stock was on the move after the pharmaceutical company announced the approval of a new cancer drug. The drug, EMRELIS, received accelerated approval from the Food and Drug ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $219.8, along ...

Citi on Wednesday upgraded Regeneron (NASDAQ:REGN) and downgraded AbbVie (NYSE:ABBV), citing varying risks for the U.S. pharma majors from the Trump administration’s latest policy moves ...

Because of today's vicious bond market-inspired selloff, this fine stock's down a quick 10 points today or more than 5%, but it only yields 3.7%. With rates going higher, you have to wonder if ...